Moreover, inhibition of USP15 leads to the decrease in TGF-β type I receptor levels and phosphorylated SMAD2 concentrations in these cells thus inhibiting TGF-β/SMAD2 signaling, and glioma progression [96]. This evidence concerns the gene SMAD2 and central nervous system cancer.